Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Investor Presentation just updated

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Nov 17, 2022 7:32pm

236 Views

Post# 35108950

RE:RE:RE:Investor Presentation just updated

I can only speculate, but because ONC is not part of any combination therapy that are approved at that time in those numbers that were run, and ONC is really a weird new up and coming science....

that the addition of pela to the mix might be an added costs above that number.

and if pela makes 75% of those drugs all work better

Well.... $$$

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China